# Colorectal Cancer FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/colorectal-cancer

> 10 upcoming FDA catalysts in colorectal Cancer: VS-7375 (VSTM) on June 2027 (primary completion); VS-7375 (VSTM) on Jun to Sep 2027 (topline data readout); petosemtamab (GMAB) on Mar to Jun 2029 (topline data readout); petosemtamab (GMAB) on March 2029 (primary completion); and 6 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 21, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Colorectal Cancer | completed | "NCT04895722 (Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-21 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04895722)) |
| June 8, 2026 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Colorectal Cancer | completed | "NCT04895722 (Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-21 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04895722?tab=results)) |
| June 16, 2026 | [XL092 primary completion](https://sec-api.dev/pdufa/xl092) | EXEL | Colorectal Cancer | completed | "NCT05425940 (Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-16 (ACTUAL); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05425940)) |
| June 2027 | [VS-7375 primary completion](https://sec-api.dev/pdufa/vs-7375) | VSTM | Colorectal Cancer | scheduled | "NCT07659795 (A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Verastem, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07659795)) |
| Jun to Sep 2027 | [VS-7375 topline data readout](https://sec-api.dev/pdufa/vs-7375) | VSTM | Colorectal Cancer | scheduled | "NCT07659795 (A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Verastem, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07659795)) |
| Mar to Jun 2029 | [Petosemtamab topline data readout](https://sec-api.dev/pdufa/petosemtamab) | GMAB | Colorectal Cancer | scheduled | "NCT07775287 (Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-30 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07775287)) |
| March 2029 | [Petosemtamab primary completion](https://sec-api.dev/pdufa/petosemtamab) | GMAB | Colorectal Cancer | scheduled | "NCT07775287 (Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-30 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07775287)) |
| May 2029 | [Telisotuzumab adizutecan primary completion](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Colorectal Cancer | scheduled | "NCT07525206 (A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07525206)) |
| May to Aug 2029 | [Telisotuzumab adizutecan topline data readout](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Colorectal Cancer | scheduled | "NCT07525206 (A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07525206)) |
| November 2029 | [Telisotuzumab adizutecan primary completion](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Colorectal Cancer | scheduled | "NCT07023289 (A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07023289)) |
| Nov 2029 to Feb 2030 | [Telisotuzumab adizutecan topline data readout](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Colorectal Cancer | scheduled | "NCT07023289 (A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07023289)) |
| Apr to Jul 2030 | [Zanzalintinib topline data readout](https://sec-api.dev/pdufa/zanzalintinib) | EXEL | Colorectal Cancer | scheduled | "NCT07750158 (Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-04-05 (ESTIMATED); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07750158)) |
| April 2030 | [Zanzalintinib primary completion](https://sec-api.dev/pdufa/zanzalintinib) | EXEL | Colorectal Cancer | scheduled | "NCT07750158 (Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-04-05 (ESTIMATED); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07750158)) |

## Drugs

- [KEYTRUDA® (pembrolizumab)](https://sec-api.dev/pdufa/pembrolizumab) (MRK)
- [XL092](https://sec-api.dev/pdufa/xl092) (EXEL)
- [VS-7375](https://sec-api.dev/pdufa/vs-7375) (VSTM)
- [Petosemtamab](https://sec-api.dev/pdufa/petosemtamab) (GMAB)
- [Telisotuzumab adizutecan](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) (ABBV)
- [Zanzalintinib](https://sec-api.dev/pdufa/zanzalintinib) (EXEL)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/colorectal-cancer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Colorectal Cancer FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/colorectal-cancer

```bibtex
@misc{secapidev_indications_colorectal_cancer_20261116,
  title        = {Colorectal Cancer FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/colorectal-cancer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_colorectal_cancer_20261116","title":"Colorectal Cancer FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/colorectal-cancer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
